株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界のアルツハイマー病市場

Global Alzheimer Market Report: 2015 Edition

発行 Koncept Analytics 商品コード 344205
出版日 ページ情報 英文 60 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.18円で換算しております。
Back to Top
世界のアルツハイマー病市場 Global Alzheimer Market Report: 2015 Edition
出版日: 2015年10月28日 ページ情報: 英文 60 Pages
概要

アルツハイマー病は、患者の記憶や日常活動を行う能力を奪う、高度な神経障害として定義されています。アルツハイマー病は、高齢人口の増加に伴って、今後数年間でねずみ算式に増加する可能性があります。

当レポートでは、世界のアルツハイマー病市場について調査分析し、市場の動向と発展、成長促進要因と課題、競合情勢、主要企業プロファイルなど、体系的な情報を提供しています。

第1章 概要

  • 認知症の定義
  • アルツハイマー病の定義

第2章 市場分析

  • 世界の認知症市場
  • 世界のアルツハイマー病市場

第3章 地域別市場

  • 米国
  • アジア太平洋地域
  • 欧州

第4章 市場力学

  • 成長促進要因
  • 主要動向と発展
  • 課題

第5章 競合情勢

第6章 企業プロファイル

  • 事業概要、財務概要、事業戦略
    • Johnson & Johnson
    • Novartis
    • Roche Holdings
    • Pfizer, Inc.
    • Forest Laboratories, Inc.

図表

目次

Alzheimer's disease is defined as an advanced neurological disorder that increasingly deprives patients of their memory and ability to carry out daily activities. As it grows in a human brain, individuals are likely to practice difficulties in linguistic, agility and insight along with negative changes in the character and performance such as depression, anxiety, delusion, hallucination and agitation. Alzheimer's disease is the main source of dementia all over the world and can be either a major or a mild neurocognitive disorder. Alzheimer's is likely to grow exponentially with increase in ageing population thus, providing a significant market opportunity in the coming years.

The current market for Alzheimer's disease drugs is limited as only few drugs have been approved thus, defining a healthy scope of introduction of new drugs in the market in the coming years. The healthcare costs associated with Alzheimer's are also anticipated to rise considerably since only limited treatment options are available in the market. The Alzheimer market expects introduction of innovative small molecules, biopharmaceuticals and disease modifying agents that would help transform the pattern of Alzheimer's disease.

Increasing ageing population, growing population of women, rising life expectancy, increasing healthcare expenditure, improving economic conditions, and increasing global spending on medicines are some of the major factors contributing to the growth of Alzheimer's disease market. However, the growth of the market is hindered by certain challenges including lack of availability of effective treatment options, problems in detection and diagnosis, and insufficient research funding.

The report, “Global Alzheimer Market” analyzes the currently prevailing condition of the market along with its future scope of development. The global market along with specific markets of the U.S., Europe (including the UK) and Asia-Pacific are being discussed in the report. The major trends, growth drivers as well as issues being faced by the industry are being presented in this report. The major players in the industry are being profiled, along with their key financials and strategies for growth.

Table of Contents

1. Overview

  • 1.1. Definition of Dementia
    • 1.1.1. Causes of Dementia
    • 1.1.2. Types of Dementia
  • 1.2. Definition of Alzheimer
    • 1.2.1. Brain Changes Related to Alzheimer
    • 1.2.2. Risks Associated with Alzheimer
    • 1.2.3. Symptoms of Alzheimer
    • 1.2.4. Diagnosis of Alzheimer
    • 1.2.5. Stages of Alzheimer
    • 1.2.6. Treatment Options for Alzheimer's disease
    • 1.2.7. Currently Available Drugs for Alzheimer Disease

2. Market Analysis

  • 2.1. Global Dementia Market
    • Global Dementia Population
    • Population by Region & Income
    • Dementia Expenditure Growth
  • 2.2. Global Alzheimer Market
    • Market Value
    • Market Share by Drug Classes

3. Regional Markets

  • 3.1. The U.S.
    • Alzheimer Prevalence
    • Prevalence by Stage & Age Group
    • Alzheimer Cost by Channel
    • Death Rate
    • Market Opportunity for New Drugs
  • 3.2. Asia-Pacific
    • Dementia Population by Countries
    • Dementia Expenditure by Countries
  • 3.3. Europe
    • Alzheimer Prevalence
  • 3.3.1. The UK
    • Dementia Prevalence
    • Prevalence by Type
    • Dementia Cost Breakup

4. Market Dynamics

  • 4.1. Growth Drivers
    • 4.1.1. Growing Ageing Population
    • 4.1.2. Increasing Population of Women
    • 4.1.3. Rising Life Expectancy
    • 4.1.4. Rising Healthcare Expenditure
    • 4.1.5. Improving Economic Conditions
    • 4.1.6. Increasing Global Spending on Medicines
  • 4.2. Key Trends and Developments
    • 4.2.1. Pipeline Drugs under Development
    • 4.2.2. Alzheimer as a Major Cause of Deaths in the U.S.
    • 4.2.3. Development of 5-HT6KKKKK Antagonists
    • 4.2.4. Higher Lifetime Risk for Women
  • 4.3. Challenges
    • 4.3.1. Lack of Effective Treatment Options
    • 4.3.2. Insufficient Research Funding
    • 4.3.3. Difficulty in Detection and Diagnosis

5. Competitive Landscape

6. Company Profiles

  • 6.1. Johnson & Johnson
    • 6.1.1. Business Overview
    • 6.1.2. Financial Overview
    • 6.1.3. Business Strategies
  • 6.2. Novartis
    • 6.2.1. Business Overview
    • 6.2.2. Financial Overview
    • 6.2.3. Business Strategies
  • 6.3. Roche Holdings
    • 6.3.1. Business Overview
    • 6.3.2. Financial Overview
    • 6.3.3. Business Strategies
  • 6.4. Pfizer, Inc.
    • 6.4.1. Business Overview
    • 6.4.2. Financial Overview
    • 6.4.3. Business Strategies
  • 6.5. Forest Laboratories, Inc.
    • 6.5.1. Business Overview
    • 6.5.2. Financial Overview
    • 6.5.3. Business Strategies

List of Charts

  • Stages of Alzheimer's disease
  • Global Dementia Population (2015E-2050E)
  • Global Dementia Population by Region (2015E)
  • Global Dementia Population by Countries (2015E)
  • Global Dementia Population by Regional Income (2015E-2050E)
  • Global New Dementia Cases by Region (2015E)
  • Global Cost of Dementia Forecast (2015-2025)
  • Global Cost of Dementia by Regional Income (2015E)
  • Global Alzheimer's Drug Market (2010-2015E)
  • Global Anti-Alzheimer's Drugs Share by Classes (2022E)
  • Alzheimer's Prevalence in the U.S. (2010-2050E)
  • Alzheimer's Prevalence in the U.S. by Age Groups (2015E)
  • Alzheimer's Prevalence in the U.S. by Stages (2015E)
  • Healthcare Cost of Alzheimer's in the U.S. by Channel (2014/2015E)
  • Healthcare Cost of Alzheimer's in the U.S. (2015E-2050E)
  • Alzheimer's Death Rate in the U.S. by Age Group (2009-2013)
  • The U.S. RTV-101 Product Market and Penetration Rate (2019E-2027E)
  • The U.S. Azeliragon Product Market and Penetration Rate (2019E-2027E)
  • Asia-Pacific Dementia Population by Countries (2015E-2050E)
  • Asia-Pacific Dementia Cost by Countries (2015E)
  • Asia-Pacific Dementia Cost by Categories (2015E)
  • Alzheimer's Total and Diagnosed Patients in Europe (2019E-2027E)
  • Europe RTV-101 Product Market and Penetration Rate (2019E-2027E)
  • Dementia Prevalence in the UK Forecast (2014-20126)
  • Dementia Prevalence in the UK by Region (2014E)
  • Dementia Prevalence in the UK by Types (2014E)
  • Dementia Cost in the UK by Categories (2014E)
  • Global Ageing Population Over 65 (2009-2014E)
  • Global Female Population, Over 45 Years (2008-2014E)
  • Global Life Expectancy Rate (2008-2014E)
  • Global Healthcare Expenditure Per Capita (2009-2014E)
  • Global GDP (2009-2014)
  • Global Spending on Medicines (2007-2017E)
  • Change in the Causes of Death (2000-2013)
  • Lifetime Risk for Alzheimer's by Age and Gender
  • Johnson & Johnson Revenue by Business Segments (2014)
  • Johnson & Johnson's Revenue and Net Income (2010-2014)
  • Novartis Revenue by Business Segments (2014)
  • Novartis Revenues (2010-2014)
  • Roche's Revenue by Business Segments (2014)
  • Roche's Revenue and Net Income (2010-2014)
  • Pfizer's Sales by Business Segments (2014)
  • Pfizer's Sales & Net Income (2010-2014)
  • Forest Laboratories Inc. Net Sales by Therapeutic Segments (2014)
  • Forest Laboratories Inc. Net Sales (2010-2014)

List of Tables

  • Types of Dementia with Symptoms and Brain Changes
  • Pipeline Drugs under Development by Category
  • Development of 5-HT6 Antagonists Drugs for Alzheimer
  • Currently Approved Drugs for Alzheimer's disease
  • Different Classes of Drugs under Development by Company
  • J&J's R&D Expenses by Segment (2013 & 2014)
Back to Top